Trevi Therapeutics (TRVI) Accumulated Expenses (2018 - 2026)

Trevi Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 75.3% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a 75.3% decrease from a year earlier, with the FY2025 full-year figure at $5.5 million, down 18.78% from the prior year.
• Accumulated Expenses fell to $1.3 million in Q1 2026 per TRVI's latest filing, from $5.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $6.8 million in Q4 2024 and bottomed at $618000.0 in Q1 2023.
• The 5-year median for Accumulated Expenses is $3.6 million (2023), against an average of $3.4 million.
• Across the five-year window, Accumulated Expenses soared 723.99% in 2022 and slumped 84.08% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $1.5 million in 2022, then jumped by 145.95% to $3.7 million in 2023, then surged by 83.61% to $6.8 million in 2024, then decreased by 18.78% to $5.5 million in 2025, then sank by 76.91% to $1.3 million in 2026.
• Per Business Quant, the three latest TRVI Accumulated Expenses figures stand at $1.3 million (Q1 2026), $5.5 million (Q4 2025), and $2.4 million (Q3 2025).